8 Best Long-Term ASX Stocks to Buy Right Now

Page 2 of 2

6. ResMed Inc. (NYSE:RMD)

With strong revenue growth projections, ResMed Inc. (NYSE:RMD) secures a spot on our list of the best long-term ASX stocks to buy right now.

On April 15, 2026, JPMorgan initiated coverage of ResMed Inc. (NYSE:RMD) with an “Overweight” rating and an A$37.60 price target, stating that the company remains well-positioned even as investor attention increasingly shifts toward GLP-1 therapies for sleep apnea.

Additionally, the firm added that although GLP-1 treatments have demonstrated meaningful clinical benefits for sleep apnea patients, they do not diminish the long-term investment case for continuous positive airway pressure therapy.

At the same time, that call is significant because one of the key concerns weighing on ResMed Inc. (NYSE:RMD) has been the positive impact of Eli Lilly’s Zepbound, which recently received U.S. approval for treating sleep apnea. This development could potentially hamper demand for ResMed’s devices.

However, ResMed Inc. (NYSE:RMD) said otherwise.

During its analyst call, alongside the fiscal Q2 2026 earnings release, management said it expects GLP-1 therapies, such as Zepbound, along with consumer sleep-tracking wearables, to expand awareness and ultimately bring more patients into the diagnosis and treatment pipeline.

Management’s stance has been straightforward: GLP-1 therapies are expected to act as a tailwind rather than a headwind for sleep apnea care and for ResMed Inc. (NYSE:RMD)’s demand pipeline.

This perspective could shift ResMed Inc. (NYSE:RMD)’s narrative away from disruption concerns toward market expansion, with increased awareness driven by these drugs potentially supporting broader adoption of the company’s core therapy platforms.

ResMed Inc. (NYSE:RMD) develops and manufactures medical devices and digital health solutions for sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions. Its products include CPAP machines, masks, and cloud-connected software platforms that enable remote patient monitoring and management.

While we acknowledge the potential of RMD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RMD and that has 100x upside potential, check out our report about the cheapest AI stock.

Click to continue reading and see the 5 best long-term ASX stocks to buy.

Disclosure: None. Follow Insider Monkey on Google News.

Page 2 of 2